Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY:MRK)

77.84 +0.86 (+1.12%)
Official Closing Price Updated: 4:10 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
From Merck & Co., Inc.
Via Business Wire
Moderna Nears Its First Breakout In Over A Year After Launching Third Cancer Vaccine Test
Moderna and Merck are now testing their cancer vaccine in patients with another form of skin cancer. 
Via Investor's Business Daily
What's Going On With Moderna Stock On Monday?
Merck's trial with Moderna's V940 for advanced cutaneous squamous cell carcinoma. The neoadjuvant and adjuvant therapy with pembrolizumab, aiming for superior event-free survival. Phase 3 expansion... 
Via Benzinga
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
From Merck & Co., Inc.
Via Business Wire
Critical Insights From Merck & Co Analyst Ratings: What You Need To Know
Via Benzinga
Analyzing Merck &amp; Co In Comparison To Competitors In Pharmaceuticals Industry
Via Benzinga
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung... 
Via Talk Markets
Exposures Product Safety
Have $2,500? 2 Superior Growth Stocks to Buy in 2024
These businesses can pack a punch in your portfolio over the long run. 
Via The Motley Fool
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth. 
Via InvestorPlace
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,... 
Via Benzinga
Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy
Gilead Sciences and Merck's Phase 2 study on islatravir and lenacapavir combo for HIV shows 94.2% viral suppression at 24 weeks. Potent antiviral activity revealed. 
Via Benzinga
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal... 
Via Benzinga
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
From Gilead Sciences, Inc.
Via Business Wire
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic
As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world. 
Via Benzinga
CASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese Patients
CASI Pharmaceuticals and BioInvent share promising results for BI-1206 in treating relapsed/refractory indolent Non-Hodgkin's Lymphoma patients in China. Preliminary data reveals clinical efficacy with... 
Via Benzinga
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Merck to Participate in the Barclays 26th Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
From FN Media Group LLC
Via GlobeNewswire
The Top 3 Dow Stocks to Buy in March 2024
Play defense with these top Dow stocks to buy as the market takes a breather from the 20% rally that started in November 2023. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Merck to Participate in the Leerink Partners Global Biopharma Conference 2024
From Merck & Co., Inc.
Via Business Wire
3 Magnificent Growth Stocks to Buy in March
These three stocks have two important common denominators: the same industry and tremendous growth prospects. 
Via The Motley Fool
Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List
Goldman Sachs is removing Apple from its Conviction List of buy-rated stocks. Looking at the potential reasons why and who replaced the tech giant. 
Via Benzinga
7 Timeless Stocks to Invest in for 2024
These are attractive timeless stocks to buy as they represent quality companies with the potential to deliver healthy total returns. 
Via InvestorPlace
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
The futures for these two beaten-down stocks could be brighter than their recent pasts. 
Via The Motley Fool
Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening
When it comes to cancer, one cannot overestimate the importance of early detection. Especially when it comes to colorectal and endometrial cancer that even big pharma companies don’t have a good track... 
Via Benzinga
3 Long-Term Winners from Charles Schwab’s Top Picks
Explore the growth and resilience of long-term stocks Microsoft, Merck and Veralto in the latest Charles Schwab stocks portfolio update. 
Via InvestorPlace
For those who appreciate value investing, NYSE:MRK is a compelling option with its solid fundamentals.
Don't overlook MERCK & CO. INC. (NYSE:MRK)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Merck to Participate in the TD Cowen 44th Annual Health Care Conference
From Merck & Co., Inc.
Via Business Wire
Why Is Cancer-Focused NGM Biopharmaceuticals Stock Trading Lower On Monday?
Explore NGM Bio's acquisition news by The Column Group at $1.55/share, an 80% premium. Learn about the recent Phase 1b study findings. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.